FDA Meeting Update: Recent discussions on social media about Plus Therapeutics (PSTV) have centered on the company’s latest announcement regarding a Type B meeting with the FDA. Many are focused on the potential acceleration of approval for REYOBIQ™, a treatment for leptomeningeal metastases. The news has sparked keen interest among investors tracking the biotech sector.
Analyst Optimism: Alongside the FDA update, social media chatter has highlighted a reaffirmed buy rating from an analyst with a price target significantly above the current stock level. Several users are debating the feasibility of this target, while others see it as a sign of confidence in the company’s pipeline. This has added fuel to ongoing conversations about PSTV’s future prospects.
Note: This discussion summary was generated from an AI condensation of post data.
Plus Therapeutics Insider Trading Activity
Plus Therapeutics insiders have traded $PSTV stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PSTV stock by insiders over the last 6 months:
- ROBERT P LENK purchased 110,000 shares for an estimated $53,779
- ANDREW JOHN HUGH MACINTYRE SIMS (Chief Financial Officer) purchased 20,000 shares for an estimated $10,200
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Plus Therapeutics Hedge Fund Activity
We have seen 18 institutional investors add shares of Plus Therapeutics stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 1,414,286 shares (+4346.2%) to their portfolio in Q3 2025, for an estimated $966,947
- ALTIUM CAPITAL MANAGEMENT LLC added 918,914 shares (+inf%) to their portfolio in Q3 2025, for an estimated $628,261
- GEODE CAPITAL MANAGEMENT, LLC added 762,074 shares (+1489.1%) to their portfolio in Q3 2025, for an estimated $521,029
- UBS GROUP AG added 536,236 shares (+611.9%) to their portfolio in Q3 2025, for an estimated $366,624
- BLACKROCK, INC. added 462,429 shares (+6644.1%) to their portfolio in Q3 2025, for an estimated $316,162
- STATE STREET CORP added 341,893 shares (+inf%) to their portfolio in Q3 2025, for an estimated $233,752
- NORTHERN TRUST CORP added 265,489 shares (+inf%) to their portfolio in Q3 2025, for an estimated $181,514
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Plus Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $PSTV in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 12/11/2025
- Ascendiant Capital issued a "Buy" rating on 11/21/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
- Maxim Group issued a "Buy" rating on 08/18/2025
To track analyst ratings and price targets for Plus Therapeutics, check out Quiver Quantitative's $PSTV forecast page.
Plus Therapeutics Price Targets
Multiple analysts have issued price targets for $PSTV recently. We have seen 4 analysts offer price targets for $PSTV in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $5.0 on 12/11/2025
- Edward Woo from Ascendiant Capital set a target price of $19.0 on 11/21/2025
- Sean Lee from HC Wainwright & Co. set a target price of $2.0 on 11/03/2025
- Jason McCarthy from Maxim Group set a target price of $3.0 on 08/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
